SBFM

Sunshine Biopharma Inc. (SBFM) | Rumor.io

Sunshine Biopharma

SBFM

Attention (50-day avg)0%

Attention rank (50-day avg)#1,861

Bullish sentiment (50-day avg)92%

Price to earnings ratio0.2

Market capitalization3.2M

Earnings per share-9.16

Dividend yield (TTM)—

Revenue (annual)36.3M

Net income (annual)-6M

Social

What share of all stock conversation is about SBFM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 26

Sunshine Biopharma ($SBFM) reports preclinical tumor suppression with K1.1 mRNA in liver cancer models.
The company plans to test K1.1 mRNA with a cancer vaccine for non-small cell lung cancer.
Sunshine Biopharma's K1.1 mRNA cancer program shows tumor-suppressing activity in liver cancer models, advancing a novel mRNA-cancer vaccine strategy.

Generated by AI

Sentiment

Of the messages about SBFM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	75% -11.6	88.82% +10.71
Bearish	—	0%	25% +11.6	11.18% -10.71

Bullish· Aug 26

Sunshine Biopharma, Inc. (SBFM) is experiencing significant price movements, with a 12.3% increase to $1.28, and has tripped a scanner multiple times, indicating strong buying activity.
The stock has a low float, making it susceptible to large price swings, and there is a significant amount of short interest, which could lead to a short squeeze and a price increase.
SBFM is on the verge of a major breakout, with a possible target price of $5, and the company's news is considered "very nice", indicating a positive outlook for the asset.

Bearish· Jun 2

Dilution is expected to negatively impact the stock, with some investors waiting for a higher price to short the asset.
The approval of a generic version of Xarelto in Canada may lead to increased competition and a significant price drop.
The stock's high fees and potential for shorting may cause it to be heavily shorted and negatively impacted.

Generated by AI

Topics

Of the messages about SBFM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	72.84%
Technical Analysis	—	—	0%	19.97%
Analysts	—	—	0%	4.2%
Controversies	—	—	0%	0.08%
Earnings	—	—	0%	2.75%
Macro	—	—	0%	0.16%

Announcements· Aug 26

Sunshine Biopharma reports preclinical tumor suppression with K1.1 mRNA in liver cancer models, advancing mRNA-cancer vaccine for difficult-to-treat lung cancer.
The company plans to test K1.1 mRNA with a cancer vaccine for non-small cell lung cancer, aiming to convert "cold" tumors into "hot" tumors.
Sunshine Biopharma's K1.1 mRNA lipid nanoparticle program shows in vivo tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma models, with a goal of developing a novel mRNA-cancer vaccine strategy.

Technical Analysis· May 22

The technical analysis suggests a bull flag formation in $SBFM, with a potential breakout above $0.60.
The chart setup indicates a parabolic move is possible, with key levels at $0.54, $0.60, and $1.00.
The analysis anticipates a continuation of the bull flag, with a potential retest of $1.00 and a long-term target of $7.00.

Generated by AI

Community

Of the messages about SBFM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	50%	36.73%	34.03%
Newcomers	—	50%	63.27%	65.97%

Regulars· Aug 26

Sunshine Biopharma has reported preclinical tumor suppression with its K1.1 mRNA in liver cancer models, and is advancing its mRNA-cancer vaccine for non-small cell lung cancer.
The company's K1.1 mRNA has shown tumor-suppressing activity in multiple in vivo hepatocellular carcinoma models, and the next phase of the program will combine K1.1 mRNA with a cancer vaccine in NSCLC.
Sunshine Biopharma is advancing its vaccine strategy for lung cancer, with the goal of converting "cold" tumors into "hot" tumors, and has demonstrated tumor-suppressing activity as a single agent in multiple in vivo models.

Newcomers· Aug 26

Newcomers to $SBFM are focusing on its recent preclinical tumor suppression results with K1.1 mRNA in liver cancer and its advances in mRNA-cancer vaccine for difficult-to-treat lung cancer.
The company's valuation is being seen as interesting, with $9.26M Q2 revenue, $13.75M cash reported at June 30, and 60 generic prescription drugs already on the Canadian market.
The stock is experiencing high volume, with 8.1M shares traded at $1.28 and 9.2M shares traded at $1.24, making it a volatile stock to watch.

Generated by AI

News

Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know

5d agoYahoo Finance

Sunshine Biopharma launches generic ondansetron in Canada

5d agoInvesting.com

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

The Company had previously published laboratory results on its library of Anti-Coronavirus compounds in August 2024 (J. 2024, 67, 13681−13702) and more recently in March 2026 (J.

13d agoYahoo Finance

EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies

Sunshine Biopharma Inc. (NASDAQ:SBFM) on Wednesday announced it advanced its lead Coronavirus drug candidate into IND-enabling studies. The company had previously published laboratory results on its library of compounds in August 2024 and more recently in March 2026. Background and Compound Research The company said that the nominated drug candidate for advanced development displayed nanomolar potency against the viral protease and had broad-spectrum activity against other SARS-CoV-2 variants of

13d agoYahoo Finance UK

Sunshine Biopharma reduces Series B warrant exercise price to $1.2046

18d agoInvesting.com

Sunshine Biopharma receives Canadian approval for atenolol tablets

29d agoInvesting.com

Also Discussed

Investors talking about SBFM also mention

#	Name	Attention
1	Creative Medical Technology Holdings, Inc.CELZ	0%0
2	Guardforce AI Co., Ltd.GFAI	0%0
3	Femto Technologies Inc.BCAN	0%0
4	Lixte Biotechnology Holdings Inc.LIXT	0%new
5	GeoVax Labs, Inc.GOVX	0%+0
6	Allarity Therapeutics Inc.ALLR	0%-0.01
7	KAVL - Kaival Brands Innovations Group, Inc.	——
8	AVAX One Technology Ltd.AGRI	0%0
9	MDVL - MedAvail Holdings, Inc.	——
10	ISPO - Inspirato Incorporated	——

Sunshine Biopharma Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing medicines for oncology, antiviral, and other prescription drug markets. The company’s current business spans prescription generic pharmaceuticals and nonprescription over-the-counter products through its operating subsidiaries, alongside a proprietary drug-development pipeline targeting areas with significant unmet medical need. Its portfolio includes generic prescription medicines available in Canada, science-based nutritional supplements, and research programs centered on small-molecule, mRNA, and protease-inhibitor candidates. Sunshine Biopharma Inc. serves as a diversified life-sciences platform that combines marketed healthcare products with ongoing therapeutic development, giving it a role in both established pharmaceutical distribution and early-stage drug innovation. Headquartered in Fort Lauderdale, Florida, the company operates primarily in the United States and Canada.

Website

Location

333 Las Olas Way

Fort Lauderdale, FL, 33301

United States

Social

What share of all stock conversation is about SBFM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 26

Sunshine Biopharma ($SBFM) reports preclinical tumor suppression with K1.1 mRNA in liver cancer models.
The company plans to test K1.1 mRNA with a cancer vaccine for non-small cell lung cancer.
Sunshine Biopharma's K1.1 mRNA cancer program shows tumor-suppressing activity in liver cancer models, advancing a novel mRNA-cancer vaccine strategy.

Generated by AI

Sentiment

Of the messages about SBFM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	75% -11.6	88.82% +10.71
Bearish	—	0%	25% +11.6	11.18% -10.71

Bullish· Aug 26

Sunshine Biopharma, Inc. (SBFM) is experiencing significant price movements, with a 12.3% increase to $1.28, and has tripped a scanner multiple times, indicating strong buying activity.
The stock has a low float, making it susceptible to large price swings, and there is a significant amount of short interest, which could lead to a short squeeze and a price increase.
SBFM is on the verge of a major breakout, with a possible target price of $5, and the company's news is considered "very nice", indicating a positive outlook for the asset.

Bearish· Jun 2

Dilution is expected to negatively impact the stock, with some investors waiting for a higher price to short the asset.
The approval of a generic version of Xarelto in Canada may lead to increased competition and a significant price drop.
The stock's high fees and potential for shorting may cause it to be heavily shorted and negatively impacted.

Generated by AI

Topics

Of the messages about SBFM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	72.84%
Technical Analysis	—	—	0%	19.97%
Analysts	—	—	0%	4.2%
Controversies	—	—	0%	0.08%
Earnings	—	—	0%	2.75%
Macro	—	—	0%	0.16%

Announcements· Aug 26

Sunshine Biopharma reports preclinical tumor suppression with K1.1 mRNA in liver cancer models, advancing mRNA-cancer vaccine for difficult-to-treat lung cancer.
The company plans to test K1.1 mRNA with a cancer vaccine for non-small cell lung cancer, aiming to convert "cold" tumors into "hot" tumors.
Sunshine Biopharma's K1.1 mRNA lipid nanoparticle program shows in vivo tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma models, with a goal of developing a novel mRNA-cancer vaccine strategy.

Technical Analysis· May 22

The technical analysis suggests a bull flag formation in $SBFM, with a potential breakout above $0.60.
The chart setup indicates a parabolic move is possible, with key levels at $0.54, $0.60, and $1.00.
The analysis anticipates a continuation of the bull flag, with a potential retest of $1.00 and a long-term target of $7.00.

Generated by AI

Community

Of the messages about SBFM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	50%	36.73%	34.03%
Newcomers	—	50%	63.27%	65.97%

Regulars· Aug 26

Sunshine Biopharma has reported preclinical tumor suppression with its K1.1 mRNA in liver cancer models, and is advancing its mRNA-cancer vaccine for non-small cell lung cancer.
The company's K1.1 mRNA has shown tumor-suppressing activity in multiple in vivo hepatocellular carcinoma models, and the next phase of the program will combine K1.1 mRNA with a cancer vaccine in NSCLC.
Sunshine Biopharma is advancing its vaccine strategy for lung cancer, with the goal of converting "cold" tumors into "hot" tumors, and has demonstrated tumor-suppressing activity as a single agent in multiple in vivo models.

Newcomers· Aug 26

Newcomers to $SBFM are focusing on its recent preclinical tumor suppression results with K1.1 mRNA in liver cancer and its advances in mRNA-cancer vaccine for difficult-to-treat lung cancer.
The company's valuation is being seen as interesting, with $9.26M Q2 revenue, $13.75M cash reported at June 30, and 60 generic prescription drugs already on the Canadian market.
The stock is experiencing high volume, with 8.1M shares traded at $1.28 and 9.2M shares traded at $1.24, making it a volatile stock to watch.

Generated by AI

Sunshine Biopharma

Social

Aug 26

Bullish· Aug 26

Bearish· Jun 2

Announcements· Aug 26

Technical Analysis· May 22

Regulars· Aug 26

Newcomers· Aug 26

Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know

Sunshine Biopharma launches generic ondansetron in Canada

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies

Sunshine Biopharma reduces Series B warrant exercise price to $1.2046

Sunshine Biopharma receives Canadian approval for atenolol tablets

Also Discussed

Sunshine Biopharma Inc.

Company Information

Location

Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know

Sunshine Biopharma launches generic ondansetron in Canada

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies

Sunshine Biopharma reduces Series B warrant exercise price to $1.2046

Sunshine Biopharma receives Canadian approval for atenolol tablets

Also Discussed

Social

Aug 26

Bullish· Aug 26

Bearish· Jun 2

Announcements· Aug 26

Technical Analysis· May 22

Regulars· Aug 26

Newcomers· Aug 26